Remove 2021 Remove Compounding Remove Vaccines
article thumbnail

Top biopharmaceutical Covid-19 vaccine companies boosted with over 80% revenue growth

Pharmaceutical Technology

Last year was a positive year for biopharmaceutical companies, particularly those with Covid-19 vaccines. As a result of huge global sales of mRNA Covid-19 vaccines, the split in profits between Pfizer and BioNTech’s Comirnaty contributed towards revenues of $81.3bn and $22.4bn last year, respectively. YoY revenue growth.

Vaccines 108
article thumbnail

CMS Finalizes Guidance on Medicare Part D Manufacturer Discount Program

The FDA Law Blog

covered insulin product or vaccine). Each phase-in program requires the manufacturer to have had a Coverage Gap Discount Program agreement in effect in 2021, and only covers applicable drugs that have been in the market as of August 16, 2022 (i.e., of the total expenditures for all Part D drugs in 2021.

Labelling 105
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

2020 review – Pharma’s progress outside of COVID-19

pharmaphorum

It has been a year dominated by the pandemic and many life sciences research projects were put on hold as big pharma turned its attention to vaccines and therapies. A molecule codenamed DNL151, currently in phase 1 development, has been selected to progress into late-stage clinical studies that are expected to begin in 2021.

FDA 93
article thumbnail

Rapid microbiology testing market growth expected 2022 to 2027

European Pharmaceutical Review

A report has predicted the rapid microbiology testing market size is estimated to grow at a compound annual growth rate (CAGR) of 9.31 The research includes historic market data from 2017 to 2021, using 2022 as the base year. million in 2017 and continued to grow until 2021. percent between 2022 and 2027.

article thumbnail

Preventing fungal contamination in pharmaceuticals

European Pharmaceutical Review

In a review on fungal-contaminated compounded pharmaceuticals and medical devices, researchers have described how the contamination of these products can be due to breaches in sterile compounding procedures. One case of drug contamination from 2021 was highlighted in the paper. Ahmed et al. Ahmed et al.

article thumbnail

STAT+: Pharmalittle: WHO pandemic accord may force pharma to disclose prices; FDA OKs first therapy to delay type 1 diabetes

STAT

The document says that public funding for the development of vaccines and treatments should be more transparent, and include provisions to ensure that any resulting products are distributed evenly around the world. The agency issued 62 warning letters and 23 import alerts related to drugs, excluding compound-related actions.

FDA 98
article thumbnail

Expectations rise for gene therapy to change treatment landscape

pharmaphorum

The sheer number of treatment candidates moving through the pipeline has seen a recent report by Polaris Market Research predicts that the market will grow at a compound annual growth rate of 17.0% from 2021 to 2029. billion in 2021. FDA backing. A broadening pipeline.

FDA 98